121 related articles for article (PubMed ID: 38265764)
21. Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition.
Dahlinger D; Duechting S; Nuecken D; Sydow K; Fuhr U; Frechen S
J Pharmacol Toxicol Methods; 2016; 77():66-75. PubMed ID: 26528794
[TBL] [Abstract][Full Text] [Related]
22. Characterisation of cytochrome P450 isoenzyme activity in sheep liver and placental microsomes.
Meakin AS; Amirmostofian M; Darby JR; Holman SL; Morrison JL; Wiese MD
Placenta; 2023 Jan; 131():82-89. PubMed ID: 36527743
[TBL] [Abstract][Full Text] [Related]
23. Contribution of the human cytochrome P450 2C subfamily to the metabolism of and the interactions with endogenous compounds including steroid hormones.
Niwa T; Yasuda S; Yamamoto Y; Murakami M; Ishii R
Pharmazie; 2021 Dec; 76(12):611-613. PubMed ID: 34986958
[TBL] [Abstract][Full Text] [Related]
24. Interaction between Changan Granule and its main components in the plasma and CYP450 enzymes.
Liu X; Wang Q; Chen M; Tao J; Wang J; Liu S; Hou J; Li D; Wang R
J Ethnopharmacol; 2023 May; 308():116303. PubMed ID: 36841379
[TBL] [Abstract][Full Text] [Related]
25. The Effects of AT-533 and AT-533 gel on Liver Cytochrome P450 Enzymes in Rats.
Wu Y; Li M; Guo Y; Liu T; Zhong L; Huang C; Ye C; Liu Q; Ren Z; Wang Y
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):345-352. PubMed ID: 35137361
[TBL] [Abstract][Full Text] [Related]
26. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
Duthaler U; Bachmann F; Suenderhauf C; Grandinetti T; Pfefferkorn F; Haschke M; Hruz P; Bouitbir J; Krähenbühl S
Clin Pharmacokinet; 2022 Jul; 61(7):1039-1055. PubMed ID: 35570253
[TBL] [Abstract][Full Text] [Related]
27. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry.
Testino SA; Patonay G
J Pharm Biomed Anal; 2003 Jan; 30(5):1459-67. PubMed ID: 12467917
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions.
Zhang W; Han F; Guo P; Zhao H; Lin ZJ; Huang MQ; Bertelsen K; Weng N
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 May; 878(15-16):1169-77. PubMed ID: 20378422
[TBL] [Abstract][Full Text] [Related]
30. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes.
Transon C; Lecoeur S; Leemann T; Beaune P; Dayer P
Eur J Clin Pharmacol; 1996; 51(1):79-85. PubMed ID: 8880056
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effects of the main metabolites of Apatinib on CYP450 isozymes in human and rat liver microsomes.
Pang NH; Xu RA; Chen LG; Chen Z; Hu GX; Zhang BW
Toxicol In Vitro; 2024 Mar; 95():105739. PubMed ID: 38042355
[TBL] [Abstract][Full Text] [Related]
32. UPLC-MS/MS analysis of the Michaelis-Menten kinetics of CYP3A-mediated midazolam 1'- and 4-hydroxylation in rat brain microsomes.
Venkatapura Chandrashekar D; DuBois B; Mehvar R
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1180():122892. PubMed ID: 34388602
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
34. LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses.
Cusinato DAC; Filgueira GCO; Rocha A; Cintra MACT; Lanchote VL; Coelho EB
J Pharm Biomed Anal; 2019 Feb; 164():430-441. PubMed ID: 30445356
[TBL] [Abstract][Full Text] [Related]
35. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
36. Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.
Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
Drug Metab Dispos; 2012 Apr; 40(4):706-16. PubMed ID: 22228749
[TBL] [Abstract][Full Text] [Related]
37. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
[TBL] [Abstract][Full Text] [Related]
38. Development of a simultaneous LC-MS/MS method to predict in vivo drug-drug interaction in mice.
Jo JJ; Jo JH; Kim S; Lee JM; Lee S
Arch Pharm Res; 2018 Apr; 41(4):450-458. PubMed ID: 29550976
[TBL] [Abstract][Full Text] [Related]
39. Effect of deglucuronidation on the results of the Basel phenotyping cocktail.
Bachmann F; Duthaler U; Krähenbühl S
Br J Clin Pharmacol; 2021 Dec; 87(12):4608-4618. PubMed ID: 33890704
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory Mechanisms of Myricetin on Human and Rat Liver Cytochrome P450 Enzymes.
Lou D; Bao SS; Li YH; Lin QM; Yang SF; He JY
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):611-618. PubMed ID: 30825074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
